GLP-1 drugs are predicted to become the top-selling pharmaceutical class ever, with projected US sales of $150 billion by 2030. I have written multiple articles on GLP-1 drugs, highlighting their ...
THE LEAD PLAINTIFF PROCESS FOR ULTRAGENYX PHARMACEUTICAL INC. INVESTORS: Ultragenyx investors may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class ...
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Annual GMP Master Class 2024" report has been added to ResearchAndMarkets.com's offering. The Annual GMP Master Class of 2024 is poised to significantly ...
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results